ADXN
ADXN
Positions held
Your positionsADXN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
2026-10-02 · Addex Therapeutics Announces Executive Management Changes
2026-10-01 · Addex Therapeutics Ltd (ADXN) (Q2 2026) Earnings Call Highlights: Regained GABAB PAM Rights and ...
2026-09-29 · Addex (ADXN) Q2 2026 Earnings Call Transcript
2026-09-28 · Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
2026-09-25 · Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
2026-09-24 · Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
2026-08-26 · ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
Price (daily)
Full chart · RSI · MACD · patterns